Investor Type

Tell us once and we'll remember.

I'm an...

Don't worry, you can always change this selection using the icons at the top left of the site.
Institutional Investor Advisor Individual Investor


Why the Health Care Rebound Has Staying Power

October 29, 2018

Senior Health Care Analysts Marshall Gordon and Nicholas Wu join Jeffrey Schulze to analyze drug pricing narratives and the health care M&A landscape, discuss opportunities created by innovation among biotechnology and pharmaceutical companies and highlight health care opportunities abroad.

Marshall Gordon

Senior Analyst - Health Care
18 Years experience
10 Years at ClearBridge

Jeffrey Schulze, CFA

Investment Strategist
13 Years experience
4 Years at ClearBridge

Nicholas Wu, PhD

Senior Analyst - Health Care
16 Years experience
11 Years at ClearBridge

Related Perspectives

  • Aggressive Growth Strategy
    October 2018 Commentary: The midterms could be a clearing event that motivates companies to put cash to work.
  • Large Cap Growth Strategy Update
    3Q18 Update: PM Margaret Vitrano discusses late-cycle technology leadership, the benefits of media consolidation and managing global trade risks.
  • Aggressive Growth Strategy
    3Q18 Commentary: Our biopharmaceutical and media holdings re-rated higher on better results and M&A.
  • Large Cap Growth Strategy
    3Q18 Commentary: Positive clinical news in the biotech industry and resolution of several media mergers were encouraging signs for the future.
  • Aggressive Growth Strategy
    August 2018 Commentary: A strong month for momentum proved a relative performance headwind for undervalued and contrarian growth names.
  • Past performance is no guarantee of future results.
    The opinions and views expressed herein are of the Portfolio Managers listed as of the date shown, and may differ from other managers, or the firm as a whole, and are not intended to be a forecast of future events, a guarantee of future results, or investment advice. The statistics have been obtained from sources believed to be reliable, but the accuracy and completeness of this information cannot be guaranteed. Neither ClearBridge Investments nor its information providers are responsible for any damages or losses arising from any use of this information.